✦ LIBER ✦

The extent of hepatectomy depends on the preoperative model for end-stage liver disease score

✍ Scribed by James D. Perkins

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 81 KB
Volume: 15
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.21773

No coin nor oath required. For personal study only.

✦ Synopsis

Objective: To produce a model indicating the extent of hepatectomy for hepatocellular carcinoma on cirrhosis based on easily available preoperative data. Design: Retrospective study based on multicenter prospectively updated databases. Setting: Two tertiary referral centers specializing in hepatobiliary surgery. Patients: A total of 466 patients undergoing hepatectomy for hepatocellular carcinoma on cirrhosis between 1995 and 2006. Main Outcome Measures: To create a decision tree for safe liver resection based on factors affecting irreversible postoperative liver failure (IPLF). Results: A total of 23 patients (4.9%) developed IPLF. The model for end-stage liver disease (MELD) score (categorized as Ͻ9, 9-10, and Ͼ10; PϽ.05 for all comparisons) and extent of hepatectomy were independent predictors of IPLF. In patients with a MELD score of less than 9, the IPLF rate was 0.4%. In patients with a MELD score of 9 or 10, the IPLF rate was 1.2% for resections of less than 1 segment, 5.1% for segmentectomies or bisegmentectomies, and 11.1% for major hepatectomies. In this category of MELD, serum sodium levels identified a low-risk group (sodium Ն140 mEq/L; to convert to millimoles per liter, multiply by 1.0) not experiencing IPLF and a high-risk group (sodium Ͻ140 mEq/L) in which resections of less than 1 segment led to an IPLF rate of 2.5% and resections of 1 segment or more led to an IPLF rate of more than 5% (PϽ.05). In patients with a MELD score of more than 10, the IPLF rate was more than 15% in all types of hepatectomies. Conclusion: A simple algorithm based on the MELD score and serum sodium level can indicate the maximum tolerable extent of hepatectomy for hepatocellular carcinoma on cirrhosis.

📜 SIMILAR VOLUMES

Model for end-stage liver disease except

Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system

✍ Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific

Clinically relevant differences in the M

Clinically relevant differences in the Model for End-Stage Liver Disease and Model for End-Stage Liver Disease–sodium scores

✍ Rhiana Garritsen; Andrei Tintu; Herold Metselaar; Geert Kazemier 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views

With interest, we read the article by Xiol et al. 1 regarding differences in serum measurements between different laboratories and their influence on the Model for End-Stage Liver Disease (MELD) and the Model for End-Stage Liver Disease incorporating serum sodium (MELD-Na). They reported significant

Impact of model for end-stage liver dise

Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis

✍ Alessandro Cucchetti; Giorgio Ercolani; Marco Vivarelli; Matteo Cescon; Matteo R 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

The objective of this study was to predict postoperative liver failure and morbidity after hepatectomy for hepatocellular carcinoma (HCC) with cirrhosis. The model for end-stage liver disease (MELD) score is currently accepted as a disease severity index of cirrhotic patients awaiting liver transpla

Reply: Clinically relevant differences i

Reply: Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores

✍ Xavier Xiol; Jose Castellote; Xavier Fuentes-Arderiu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 1 views

We thank Garritsen et al. 1 for their interest in our article about differences in Model for End-Stage Liver Disease (MELD) and Model for End-Stage Liver Disease-Sodium (MELD-Na) scores determined at 3 different laboratories. 2 We agree that one of the important messages of our article is the import

The model for end-stage liver disease sc

The model for end-stage liver disease score and posttransplant biliary complications

✍ Domingo Balderramo; Andres Cardenas 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Clinically relevant differences in the m

Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease–sodium scores determined at three university-based laboratories of the same area

✍ Xavier Xiol; Pere Gines; Lluis Castells; Jorge Twose; Alba Ribalta; Xavier Fuent 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

The Model for End-Stage Liver Disease (MELD) score is considered an objective and reliable measure of liver disease severity. However, the use of specific laboratory methodologies may introduce significant and clinically relevant variations into the score. It has been suggested that the incorporatio